Leif Stenke

7.0k citations
116 papers · 3.3k · 1 hit paper · h-index 29

Impact in

  • Hematology top 0.2%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.5%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Chronic Myeloid Leukemia Treatments 66
    • Acute Myeloid Leukemia Research 21
    • Chronic Lymphocytic Leukemia Research 39
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 6

Leif Stenke

115 papers receiving 3.2k citations

Leif Stenke's Hit Papers

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia 2013 · 481 citations
4810+4+8Years since publication100200300400

Peers

Leif Stenke
Comparison fields: 5 of 107
  • Hematology 2.1k
  • Genetics 1.1k
  • Rheumatology 507
  • Oncology 772
  • Immunology 489
Replace Francis J. Giles with:
Francis J. Giles United States
Ronan Swords United States
Ilene Galinsky United States
John E. Godwin United States
Florian H. Heidel Germany
Jessica K. Altman United States
Karoline V. Gleixner Austria
H. Jean Khoury United States
Olatoyosi Odenike United States
Ji Yuan Wu United States
Leif Stenke relative to Francis J. Giles United States Francis J. Giles's profile →
Citations per field
00.5×2×3×3.5×
Francis J. Giles · 1×
Citations per year

Countries citing papers authored by Leif Stenke

Since Specialization
Citations

This map shows the geographic impact of Leif Stenke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leif Stenke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leif Stenke more than expected).

Fields of papers citing papers by Leif Stenke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leif Stenke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leif Stenke. The network helps show where Leif Stenke may publish in the future.

Co-authors

The 25 scholars most cited alongside Leif Stenke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Leif Stenke Line = papers co-authored together Leif Stenke links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Hit paper breakdown →
2013481
2 2011389
3 2009236
4 2009135
5 2010127
6 201798
7 201389
8 200083
9 201173
10 201672
11 201558
12 199156
13 199356
14 201454
15 199149
16 201649
17 201448
18 201547
19
Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
199344
20 199140

About Leif Stenke

Leif Stenke is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Oncology, having authored 116 papers that have together received 3.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (66 papers), Chronic Lymphocytic Leukemia Research (39 papers), Eosinophilic Disorders and Syndromes (24 papers), Acute Myeloid Leukemia Research (21 papers), Acute Lymphoblastic Leukemia research (11 papers), Immune Cell Function and Interaction (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Mast cells and histamine (6 papers). The work is most often cited by research in Hematology (2.1k citations), Genetics (1.1k citations), Rheumatology (507 citations), Oncology (772 citations) and Immunology (489 citations). Leif Stenke has collaborated with scholars based in Sweden, Finland and United States. Frequent co-authors include Satu Mustjoki, Peter Reizenstein, Richard A. Larson, Martin Höglund, Johan Richter, Martin S. Tallman, Marilyn L. Slovak, Stephen H. Petersdorf, Thomas J. Nevill and Harry P. Erba. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Leukemia and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact